[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) Form 144 notice: An affiliate proposes to sell 42,237 shares of common stock through Morgan Stanley Smith Barney LLC on 08/21/2025, with an aggregate market value of $2,090,076.83. The filing lists total outstanding shares of 191,168,504. The securities to be sold were acquired as restricted stock on multiple dates (08/16/2024; 11/16/2024; 02/16/2025; 05/16/2025; 08/16/2025) in amounts shown in the filing.

The filing also discloses sales by Thomas Trimarchi on 08/18/2025 totaling 17,353 shares for gross proceeds of $871,722.75. The notice contains the seller's certification that no undisclosed material adverse information is known to the signer.

Positive

• None.

Negative

• Planned insider sale of 42,237 shares with aggregate market value of $2,090,076.83 scheduled for 08/21/2025
• Recent insider sales by Thomas Trimarchi on 08/18/2025 totaled 17,353 shares for gross proceeds of $871,722.75

Insights

Securities Analyst

TL;DR: Insider plans to sell 42,237 shares (0.022% of outstanding) via Morgan Stanley on 08/21/2025; recent insider sales totaled 17,353 shares for $871,722.75.

The filing is a routine Form 144 disclosure showing an intended sale of restricted stock by an affiliate/insider. The size of the proposed sale (42,237 shares, aggregate market value $2.09M) is small relative to the reported outstanding shares (191.17M), suggesting limited direct dilution or market impact solely from this transaction. Recent sales by the same name on 08/18/2025 totaling 17,353 shares and $871,722.75 in proceeds are documented and should be considered when assessing insider disposition activity.

Compliance/Risk Analyst

TL;DR: Form 144 properly lists acquisition dates, restricted stock nature, broker, and recent sales; signer certifies absence of undisclosed material adverse information.

The disclosure includes required details: broker name, exact share counts, acquisition dates and nature (restricted stock), and recent sales by the filer. The filing contains the standard attestation regarding material adverse information and warns against intentional misstatements. No regulatory exceptions or missing mandatory fields are evident within the provided content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	42237	2090076.83	191168504	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/16/2024	Restricted Stock	Issuer			10558	08/16/2024	Not Applicable
Common	08/16/2025	Restricted Stock	Issuer			17230	08/16/2025	Not Applicable
Common	05/16/2025	Restricted Stock	Issuer			3577	05/16/2025	Not Applicable
Common	11/16/2024	Restricted Stock	Issuer			10558	11/16/2024	Not Applicable
Common	02/16/2025	Restricted Stock	Issuer			314	02/16/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
THOMAS TRIMARCHI 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/18/2025	4757	238966.47
THOMAS TRIMARCHI 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/18/2025	3284	164970.75
THOMAS TRIMARCHI 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/18/2025	3048	153115.37
THOMAS TRIMARCHI 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/18/2025	6264	314670.16

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many BridgeBio (BBIO) shares are proposed for sale in this Form 144?

The filing proposes the sale of 42,237 shares of common stock.

What is the aggregate market value of the proposed BBIO sale?

The aggregate market value is reported as $2,090,076.83.

Who is the broker handling the proposed sale for BBIO shares?

The broker listed is Morgan Stanley Smith Barney LLC.

When is the approximate date of the proposed BBIO sale?

The approximate date of sale is 08/21/2025.

What recent sales by the filer are disclosed in the filing?

The filing shows Thomas Trimarchi sold 17,353 shares on 08/18/2025 for gross proceeds of $871,722.75.

How were the securities being sold originally acquired?

All listed securities to be sold were acquired as restricted stock on the dates shown in the filing.